ID   SQSTM_RAT               Reviewed;         439 AA.
AC   O08623; Q8CH59;
DT   11-OCT-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-JUL-1997, sequence version 1.
DT   02-OCT-2024, entry version 188.
DE   RecName: Full=Sequestosome-1;
DE   AltName: Full=Protein kinase C-zeta-interacting protein;
DE            Short=PKC-zeta-interacting protein;
DE   AltName: Full=Ubiquitin-binding protein p62;
GN   Name=Sqstm1; Synonyms=Zip;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY,
RP   OLIGOMERIZATION, PHOSPHORYLATION, SUBCELLULAR LOCATION, AND INTERACTION
RP   WITH PRKCZ.
RC   TISSUE=Brain;
RX   PubMed=9177193; DOI=10.1073/pnas.94.12.6191;
RA   Puls A., Schmidt S., Grawe F., Stabel S.;
RT   "Interaction of protein kinase C zeta with ZIP, a novel protein kinase C-
RT   binding protein.";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:6191-6196(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), TISSUE SPECIFICITY,
RP   OLIGOMERIZATION, AND INTERACTION WITH GABRR1; GABRR2; GABRR3; PRKCZ AND
RP   KCNAB2.
RC   STRAIN=Sprague-Dawley; TISSUE=Brain;
RX   PubMed=12431995; DOI=10.1074/jbc.m205162200;
RA   Croci C., Brandstaetter J.H., Enz R.;
RT   "ZIP3, a new splice variant of the PKC-zeta-interacting protein family,
RT   binds to GABAC receptors, PKC-zeta, and Kv beta 2.";
RL   J. Biol. Chem. 278:6128-6135(2003).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Pituitary;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   INDUCTION, AND TISSUE SPECIFICITY.
RX   PubMed=10366737; DOI=10.1016/s0169-328x(99)00093-5;
RA   Nakaso K., Kitayama M., Ishii T., Bannai S., Yanagawa T., Kimura K.,
RA   Nakashima K., Ohama E., Yamada K.;
RT   "Effects of kainate-mediated excitotoxicity on the expression of rat
RT   counterparts of A170 and MSP23 stress proteins in the brain.";
RL   Brain Res. Mol. Brain Res. 69:155-163(1999).
RN   [5]
RP   ALTERNATIVE SPLICING (ISOFORM 2), TISSUE SPECIFICITY, INTERACTION WITH
RP   KCNAB1; KCNAB2 AND PRKCZ, OLIGOMERIZATION, DEVELOPMENTAL STAGE, INDUCTION,
RP   AND FUNCTION.
RX   PubMed=10477520; DOI=10.1126/science.285.5433.1565;
RA   Gong J., Xu J., Bezanilla M., van Huizen R., Derin R., Li M.;
RT   "Differential stimulation of PKC phosphorylation of potassium channels by
RT   ZIP1 and ZIP2.";
RL   Science 285:1565-1569(1999).
RN   [6]
RP   INDUCTION.
RX   PubMed=11162503; DOI=10.1006/bbrc.2000.4107;
RA   Kuusisto E., Suuronen T., Salminen A.;
RT   "Ubiquitin-binding protein p62 expression is induced during apoptosis and
RT   proteasomal inhibition in neuronal cells.";
RL   Biochem. Biophys. Res. Commun. 280:223-228(2001).
RN   [7]
RP   INTERACTION WITH NTRK1; TRAF6 AND PRKCZ, AND FUNCTION.
RX   PubMed=11244088; DOI=10.1074/jbc.c000869200;
RA   Wooten M.W., Seibenhener M.L., Mamidipudi V., Diaz-Meco M.T., Barker P.A.,
RA   Moscat J.;
RT   "The atypical protein kinase C-interacting protein p62 is a scaffold for
RT   NF-kappaB activation by nerve growth factor.";
RL   J. Biol. Chem. 276:7709-7712(2001).
RN   [8]
RP   INTERACTION WITH PRKCZ, SUBCELLULAR LOCATION, AND FUNCTION.
RX   PubMed=11500922; DOI=10.1002/jcb.1177;
RA   Samuels I.S., Seibenhener M.L., Neidigh K.B.W., Wooten M.W.;
RT   "Nerve growth factor stimulates the interaction of ZIP/p62 with atypical
RT   protein kinase C and targets endosomal localization: evidence for
RT   regulation of nerve growth factor-induced differentiation.";
RL   J. Cell. Biochem. 82:452-466(2001).
RN   [9]
RP   INDUCTION.
RX   PubMed=11981755; DOI=10.1053/jhep.2002.32674;
RA   Stumptner C., Fuchsbichler A., Heid H., Zatloukal K., Denk H.;
RT   "Mallory body -- a disease-associated type of sequestosome.";
RL   Hepatology 35:1053-1062(2002).
RN   [10]
RP   INDUCTION.
RX   PubMed=15158159; DOI=10.1016/j.brainres.2004.03.029;
RA   Nakaso K., Yoshimoto Y., Nakano T., Takeshima T., Fukuhara Y., Yasui K.,
RA   Araga S., Yanagawa T., Ishii T., Nakashima K.;
RT   "Transcriptional activation of p62/A170/ZIP during the formation of the
RT   aggregates: possible mechanisms and the role in Lewy body formation in
RT   Parkinson's disease.";
RL   Brain Res. 1012:42-51(2004).
RN   [11]
RP   INTERACTION WITH PRKCI, AND MUTAGENESIS OF LYS-7; 21-ARG-ARG-22; ASP-67 AND
RP   ARG-94.
RX   PubMed=15143057; DOI=10.1074/jbc.m403092200;
RA   Hirano Y., Yoshinaga S., Ogura K., Yokochi M., Noda Y., Sumimoto H.,
RA   Inagaki F.;
RT   "Solution structure of atypical protein kinase C PB1 domain and its mode of
RT   interaction with ZIP/p62 and MEK5.";
RL   J. Biol. Chem. 279:31883-31890(2004).
RN   [12]
RP   INTERACTION WITH IKBKB; PRKCI AND TRAF6.
RX   PubMed=16079148; DOI=10.1074/jbc.c500237200;
RA   Wooten M.W., Geetha T., Seibenhener M.L., Babu J.R., Diaz-Meco M.T.,
RA   Moscat J.;
RT   "The p62 scaffold regulates nerve growth factor-induced NF-kappaB
RT   activation by influencing TRAF6 polyubiquitination.";
RL   J. Biol. Chem. 280:35625-35629(2005).
RN   [13]
RP   INTERACTION WITH NBR1 AND TRIM55, AND SUBCELLULAR LOCATION.
RX   PubMed=15802564; DOI=10.1126/science.1110463;
RA   Lange S., Xiang F., Yakovenko A., Vihola A., Hackman P., Rostkova E.,
RA   Kristensen J., Brandmeier B., Franzen G., Hedberg B., Gunnarsson L.G.,
RA   Hughes S.M., Marchand S., Sejersen T., Richard I., Edstroem L., Ehler E.,
RA   Udd B., Gautel M.;
RT   "The kinase domain of titin controls muscle gene expression and protein
RT   turnover.";
RL   Science 308:1599-1603(2005).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-266 AND SER-354, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22673903; DOI=10.1038/ncomms1871;
RA   Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A., Lundby C.,
RA   Olsen J.V.;
RT   "Quantitative maps of protein phosphorylation sites across 14 different rat
RT   organs and tissues.";
RL   Nat. Commun. 3:876-876(2012).
RN   [15]
RP   STRUCTURE BY NMR OF 3-100, SUBUNIT, AND MUTAGENESIS OF ASP-67 AND ASP-69.
RX   PubMed=19728111; DOI=10.1007/s10858-009-9370-7;
RA   Saio T., Yokochi M., Inagaki F.;
RT   "The NMR structure of the p62 PB1 domain, a key protein in autophagy and
RT   NF-kappaB signaling pathway.";
RL   J. Biomol. NMR 45:335-341(2009).
CC   -!- FUNCTION: Molecular adapter required for selective macroautophagy
CC       (aggrephagy) by acting as a a bridge between polyubiquitinated proteins
CC       and autophagosomes (By similarity). Promotes the recruitment of
CC       ubiquitinated cargo proteins to autophagosomes via multiple domains
CC       that bridge proteins and organelles in different steps (By similarity).
CC       SQSTM1 first mediates the assembly and removal of ubiquitinated
CC       proteins by undergoing liquid-liquid phase separation upon binding to
CC       ubiquitinated proteins via its UBA domain, leading to the formation of
CC       insoluble cytoplasmic inclusions, known as p62 bodies (By similarity).
CC       SQSTM1 then interacts with ATG8 family proteins on autophagosomes via
CC       its LIR motif, leading to p62 body recruitment to autophagosomes,
CC       followed by autophagic clearance of ubiquitinated proteins (By
CC       similarity). SQSTM1 is itself degraded along with its ubiquitinated
CC       cargos (By similarity). Also required to recruit ubiquitinated proteins
CC       to PML bodies in the nucleus (By similarity). Also involved in
CC       autophagy of peroxisomes (pexophagy) in response to reactive oxygen
CC       species (ROS) by acting as a bridge between ubiquitinated PEX5 receptor
CC       and autophagosomes (By similarity). Acts as an activator of the
CC       NFE2L2/NRF2 pathway via interaction with KEAP1: interaction inactivates
CC       the BCR(KEAP1) complex by sequestering the complex in inclusion bodies,
CC       promoting nuclear accumulation of NFE2L2/NRF2 and subsequent expression
CC       of cytoprotective genes (By similarity). Promotes relocalization of
CC       'Lys-63'-linked ubiquitinated STING1 to autophagosomes (By similarity).
CC       Involved in endosome organization by retaining vesicles in the
CC       perinuclear cloud: following ubiquitination by RNF26, attracts specific
CC       vesicle-associated adapters, forming a molecular bridge that restrains
CC       cognate vesicles in the perinuclear region and organizes the endosomal
CC       pathway for efficient cargo transport (By similarity). Sequesters
CC       tensin TNS2 into cytoplasmic puncta, promoting TNS2 ubiquitination and
CC       proteasomal degradation (By similarity). May regulate the activation of
CC       NFKB1 by TNF-alpha, nerve growth factor (NGF) and interleukin-1
CC       (PubMed:11244088, PubMed:11500922). May play a role in titin/TTN
CC       downstream signaling in muscle cells (By similarity). Adapter that
CC       mediates the interaction between TRAF6 and CYLD (By similarity).
CC       {ECO:0000250|UniProtKB:Q13501, ECO:0000250|UniProtKB:Q64337,
CC       ECO:0000269|PubMed:11244088, ECO:0000269|PubMed:11500922}.
CC   -!- FUNCTION: [Isoform 1]: More potent than isoform 2 to stimulate PRKCZ-
CC       dependent phosphorylation of KCNAB2. {ECO:0000269|PubMed:10477520}.
CC   -!- SUBUNIT: Homooligomer or heterooligomer; may form homotypic arrays
CC       (PubMed:10477520, PubMed:19728111, PubMed:9177193). Dimerization
CC       interferes with ubiquitin binding. Component of a ternary complex with
CC       PAWR and PRKCZ (By similarity). Forms a complex with JUB/Ajuba, PRKCZ
CC       and TRAF6 (By similarity). Identified in a complex with TRAF6 and CYLD
CC       (By similarity). Identified in a heterotrimeric complex with ubiquitin
CC       and ZFAND5, where ZFAND5 and SQSTM1 both interact with the same
CC       ubiquitin molecule (By similarity). Interacts (via LIR motif) with
CC       MAP1LC3A and MAP1LC3B, as well as with other ATG8 family members,
CC       including GABARAP, GABARAPL1 and GABARAPL2; these interactions are
CC       necessary for the recruitment MAP1 LC3 family members to inclusion
CC       bodies containing polyubiquitinated protein aggregates and for their
CC       degradation by autophagy (By similarity). Interacts directly with PRKCI
CC       and PRKCZ (PubMed:11244088, PubMed:11500922, PubMed:15143057,
CC       PubMed:16079148). Interacts with EBI3, LCK, RASA1, NR2F2, NTRK1, NTRK2,
CC       NTRK3, NBR1, MAP2K5 and MAPKAPK5 (PubMed:11244088). Upon TNF-alpha
CC       stimulation, interacts with RIPK1 probably bridging IKBKB to the TNF-R1
CC       complex composed of TNF-R1/TNFRSF1A, TRADD and RIPK1 (PubMed:16079148).
CC       Interacts with the proteasome subunits PSMD4 and PSMC2 (By similarity).
CC       Interacts with TRAF6 (PubMed:11244088, PubMed:16079148). Interacts with
CC       'Lys-63'-linked polyubiquitinated MAPT/TAU. Interacts with FHOD3.
CC       Interacts with CYLD. Interacts with SESN1. Interacts with SESN2 (By
CC       similarity). Interacts with ULK1 (By similarity). Interacts with UBD
CC       (By similarity). Interacts with WDR81; the interaction is direct and
CC       regulates the interaction of SQSTM1 with ubiquitinated proteins (By
CC       similarity). Interacts with WDFY3; this interaction is required to
CC       recruit WDFY3 to cytoplasmic bodies and to PML bodies (By similarity).
CC       Interacts with LRRC25 (By similarity). Interacts with STING1; leading
CC       to relocalization of STING1 to autophagosomes (By similarity).
CC       Interacts (when phosphorylated at Ser-348) with KEAP1; the interaction
CC       is direct and inactivates the BCR(KEAP1) complex by sequestering KEAP1
CC       in inclusion bodies, promoting its degradation (By similarity).
CC       Interacts with MOAP1; promoting dissociation of SQSTM1 inclusion bodies
CC       that sequester KEAP1 (By similarity). Interacts with GBP1 (By
CC       similarity). Interacts with TAX1BP1 (By similarity). Interacts with
CC       (ubiquitinated) PEX5; specifically binds PEX5 ubiquitinated at 'Lys-
CC       209' in response to reactive oxygen species (ROS) (By similarity).
CC       Interacts (via PB1 domain) with TNS2; the interaction leads to
CC       sequestration of TNS2 in cytoplasmic aggregates with SQSTM1 and
CC       promotes TNS2 ubiquitination and proteasomal degradation (By
CC       similarity). Interacts with IRS1; the interaction is disrupted by the
CC       presence of tensin TNS2 (By similarity). Interacts witH TRIM5 (By
CC       similarity). Interacts with TRIM11 (when ubiquitinated); promoting AIM2
CC       recruitment to autophagosomes and autophagy-dependent degradation of
CC       AIM2 (By similarity). Interacts with TRIM13 (By similarity). Interacts
CC       with TRIM16 (By similarity). Interacts with TRIM23 (By similarity).
CC       Interacts with TRIM50 (By similarity). Interacts with TRIM55
CC       (PubMed:15802564). Interacts with ECSIT; this interaction inhibits TLR4
CC       signaling via functional regulation of the TRAF6-ECSIT complex (By
CC       similarity). Interacts with GABRR1, GABRR2 and GABRR3
CC       (PubMed:12431995). Interacts with WDR83 (By similarity). Interacts with
CC       GRB2 (By similarity). {ECO:0000250|UniProtKB:Q13501,
CC       ECO:0000250|UniProtKB:Q64337, ECO:0000269|PubMed:10477520,
CC       ECO:0000269|PubMed:11244088, ECO:0000269|PubMed:11500922,
CC       ECO:0000269|PubMed:12431995, ECO:0000269|PubMed:15143057,
CC       ECO:0000269|PubMed:15802564, ECO:0000269|PubMed:16079148,
CC       ECO:0000269|PubMed:19728111, ECO:0000269|PubMed:9177193}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasmic vesicle, autophagosome
CC       {ECO:0000250|UniProtKB:Q13501}. Preautophagosomal structure
CC       {ECO:0000250|UniProtKB:Q13501}. Cytoplasm, cytosol
CC       {ECO:0000250|UniProtKB:Q64337}. Nucleus, PML body
CC       {ECO:0000250|UniProtKB:Q13501}. Late endosome
CC       {ECO:0000250|UniProtKB:Q13501}. Lysosome
CC       {ECO:0000250|UniProtKB:Q13501}. Nucleus {ECO:0000250|UniProtKB:Q64337}.
CC       Endoplasmic reticulum {ECO:0000250|UniProtKB:Q13501}. Cytoplasm,
CC       myofibril, sarcomere {ECO:0000269|PubMed:15802564}. Note=In cardiac
CC       muscle, localizes to the sarcomeric band (PubMed:15802564). Localizes
CC       to cytoplasmic membraneless inclusion bodies, known as p62 bodies,
CC       containing polyubiquitinated protein aggregates (By similarity). In
CC       protein aggregate diseases of the liver, found in large amounts in
CC       Mallory bodies of alcoholic and nonalcoholic steatohepatitis, hyaline
CC       bodies in hepatocellular carcinoma, and in SERPINA1 aggregates.
CC       Enriched in Rosenthal fibers of pilocytic astrocytoma. In the
CC       cytoplasm, observed in both membrane-free ubiquitin-containing protein
CC       aggregates (sequestosomes) and membrane-surrounded autophagosomes.
CC       Colocalizes with TRIM13 in the perinuclear endoplasmic reticulum. Co-
CC       localizes with TRIM5 in cytoplasmic bodies. When nuclear export is
CC       blocked by treatment with leptomycin B, accumulates in PML bodies (By
CC       similarity). {ECO:0000250|UniProtKB:Q13501,
CC       ECO:0000250|UniProtKB:Q64337, ECO:0000269|PubMed:15802564}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1; Synonyms=Zip1, B20;
CC         IsoId=O08623-1; Sequence=Displayed;
CC       Name=2; Synonyms=Zip2, B24;
CC         IsoId=O08623-2; Sequence=VSP_015843;
CC       Name=3; Synonyms=Zip3;
CC         IsoId=O08623-3; Sequence=VSP_015844, VSP_015845;
CC   -!- TISSUE SPECIFICITY: Ubiquitously expressed. In brain, mainly expressed
CC       by neurons, especially pyramidal neurons in the cerebral cortex and
CC       hippocampus. Also expressed by Purkinje cells and neurons in the
CC       dentate nucleus of the cerebellum and neurons of the basal ganglia (at
CC       protein level). {ECO:0000269|PubMed:10366737,
CC       ECO:0000269|PubMed:10477520, ECO:0000269|PubMed:12431995,
CC       ECO:0000269|PubMed:9177193}.
CC   -!- DEVELOPMENTAL STAGE: Maximal expression is detected at postnatal day 13
CC       (P13) (at protein level). {ECO:0000269|PubMed:10477520}.
CC   -!- INDUCTION: By the proteasome inhibitors MG132 and lactacystin. By
CC       intoxication with 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DCC). By
CC       okadaic acid and kainate (at protein level). Isoform 1 and isoform 2
CC       relative amounts are changed upon up-regulation of the expression by
CC       NGF. {ECO:0000269|PubMed:10366737, ECO:0000269|PubMed:10477520,
CC       ECO:0000269|PubMed:11162503, ECO:0000269|PubMed:11981755,
CC       ECO:0000269|PubMed:15158159}.
CC   -!- DOMAIN: The UBA domain binds specifically 'Lys-63'-linked polyubiquitin
CC       chains of polyubiquitinated substrates (By similarity). Mediates the
CC       interaction with TRIM55. Both the UBA and PB1 domains are necessary and
CC       sufficient for the localization into the ubiquitin-containing inclusion
CC       bodies (By similarity). {ECO:0000250|UniProtKB:Q13501,
CC       ECO:0000250|UniProtKB:Q64337}.
CC   -!- DOMAIN: The PB1 domain mediates homooligomerization and interactions
CC       with FHOD3, MAP2K5, NBR1, PRKCI, PRKCZ and WDR81. Both the PB1 and UBA
CC       domains are necessary and sufficient for the localization into the
CC       ubiquitin-containing inclusion bodies. {ECO:0000250|UniProtKB:Q13501}.
CC   -!- DOMAIN: The ZZ-type zinc finger mediates the interaction with RIPK1.
CC       {ECO:0000250|UniProtKB:Q13501}.
CC   -!- DOMAIN: The LIR (LC3-interacting region) motif mediates the interaction
CC       with ATG8 family proteins. {ECO:0000250|UniProtKB:Q64337}.
CC   -!- PTM: Phosphorylated (PubMed:9177193). Phosphorylation at Ser-406 by
CC       ULK1 destabilizes the UBA dimer interface and increases binding
CC       affinity to ubiquitinated proteins. Phosphorylation at Ser-406 also
CC       primes for subsequent phosphorylation at Ser-402 (By similarity).
CC       Phosphorylation at Ser-402 by CK2 or ULK1 promotes binding to
CC       ubiquitinated proteins by increasing the affinity between the UBA
CC       domain and polyubiquitin chains. Phosphorylation at Ser-402 by ULK1 is
CC       stimulated by SESN2. Phosphorylated at Ser-402 by TBK1, leading to
CC       promote relocalization of 'Lys-63'-linked ubiquitinated STING1 to
CC       autophagosomes. Phosphorylation at Ser-348 by ULK1 promotes interaction
CC       with KEAP1 and inactivation of the BCR(KEAP1) complex, promoting
CC       NFE2L2/NRF2 nuclear accumulation and expression of phase II detoxifying
CC       enzymes. Phosphorylated in vitro by TTN (By similarity).
CC       {ECO:0000250|UniProtKB:Q13501, ECO:0000250|UniProtKB:Q64337,
CC       ECO:0000269|PubMed:9177193}.
CC   -!- PTM: Ubiquitinated by UBE2J1 and RNF26 at Lys-434: ubiquitinated SQSTM1
CC       attracts specific vesicle-associated adapters, forming a molecular
CC       bridge that restrains cognate vesicles in the perinuclear region and
CC       organizes the endosomal pathway for efficient cargo transport.
CC       Ubiquitination by UBE2D2 and UBE2D3 increases its ability to bind
CC       polyubiquitin chains by destabilizing the UBA dimer interface.
CC       Deubiquitination by USP15 releases target vesicles for fast transport
CC       into the cell periphery. Ubiquitinated by the BCR(KEAP1) complex at
CC       Lys-419, increasing SQSTM1 sequestering activity and promoting its
CC       degradation. Ubiquitinated via 'Lys-29' and 'Lys-33'-linked
CC       polyubiquitination leading to xenophagic targeting of bacteria and
CC       inhibition of their replication. {ECO:0000250|UniProtKB:Q13501}.
CC   -!- PTM: Acetylated at Lys-419 and Lys-434 by KAT5/TIP60, promotes activity
CC       by destabilizing the UBA dimer interface and increases binding affinity
CC       to ubiquitinated proteins. Deacetylated by HDAC6.
CC       {ECO:0000250|UniProtKB:Q13501}.
CC   -!- PTM: Palmitoylation at Cys-288 by ZDHHC19 is required for efficient
CC       autophagic degradation of SQSTM1-cargo complexes by promoting affinity
CC       for ATG8 proteins and recruitment of p62 bodies to autophagosomes.
CC       Dealmitoylated at Cys-288 by LYPLA1. {ECO:0000250|UniProtKB:Q13501}.
CC   -!- MISCELLANEOUS: [Isoform 1]: Major isoform except in central nervous
CC       system.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; Y08355; CAA69642.1; -; mRNA.
DR   EMBL; AF439403; AAO15463.1; -; mRNA.
DR   EMBL; BC061575; AAH61575.1; -; mRNA.
DR   RefSeq; NP_787037.2; NM_175843.4. [O08623-1]
DR   RefSeq; NP_853528.1; NM_181550.1.
DR   RefSeq; XP_006246275.1; XM_006246213.2.
DR   PDB; 2K6Q; NMR; -; B=331-346.
DR   PDB; 2KKC; NMR; -; A=3-100.
DR   PDB; 2KTR; NMR; -; A/B=3-100.
DR   PDBsum; 2K6Q; -.
DR   PDBsum; 2KKC; -.
DR   PDBsum; 2KTR; -.
DR   AlphaFoldDB; O08623; -.
DR   BMRB; O08623; -.
DR   SMR; O08623; -.
DR   BioGRID; 250206; 31.
DR   CORUM; O08623; -.
DR   IntAct; O08623; 5.
DR   MINT; O08623; -.
DR   STRING; 10116.ENSRNOP00000056021; -.
DR   iPTMnet; O08623; -.
DR   PhosphoSitePlus; O08623; -.
DR   jPOST; O08623; -.
DR   PaxDb; 10116-ENSRNOP00000056021; -.
DR   Ensembl; ENSRNOT00000004308.7; ENSRNOP00000004308.7; ENSRNOG00000003147.9. [O08623-2]
DR   Ensembl; ENSRNOT00000059255.6; ENSRNOP00000056021.3; ENSRNOG00000003147.9. [O08623-1]
DR   Ensembl; ENSRNOT00055032512; ENSRNOP00055026330; ENSRNOG00055019045. [O08623-1]
DR   Ensembl; ENSRNOT00060033594; ENSRNOP00060027499; ENSRNOG00060019383. [O08623-1]
DR   Ensembl; ENSRNOT00065009426; ENSRNOP00065006759; ENSRNOG00065006177. [O08623-1]
DR   GeneID; 113894; -.
DR   KEGG; rno:113894; -.
DR   UCSC; RGD:69287; rat. [O08623-1]
DR   AGR; RGD:69287; -.
DR   CTD; 8878; -.
DR   RGD; 69287; Sqstm1.
DR   eggNOG; KOG4582; Eukaryota.
DR   GeneTree; ENSGT00390000002781; -.
DR   HOGENOM; CLU_038011_1_0_1; -.
DR   InParanoid; O08623; -.
DR   OMA; NCNGWLT; -.
DR   OrthoDB; 1329809at2759; -.
DR   PhylomeDB; O08623; -.
DR   Reactome; R-RNO-205043; NRIF signals cell death from the nucleus.
DR   Reactome; R-RNO-209543; p75NTR recruits signalling complexes.
DR   Reactome; R-RNO-209560; NF-kB is activated and signals survival.
DR   Reactome; R-RNO-5205685; PINK1-PRKN Mediated Mitophagy.
DR   Reactome; R-RNO-9020702; Interleukin-1 signaling.
DR   Reactome; R-RNO-9664873; Pexophagy.
DR   Reactome; R-RNO-9755511; KEAP1-NFE2L2 pathway.
DR   EvolutionaryTrace; O08623; -.
DR   PRO; PR:O08623; -.
DR   Proteomes; UP000002494; Chromosome 10.
DR   Bgee; ENSRNOG00000003147; Expressed in skeletal muscle tissue and 19 other cell types or tissues.
DR   ExpressionAtlas; O08623; baseline and differential.
DR   GO; GO:0016235; C:aggresome; ISO:RGD.
DR   GO; GO:0044753; C:amphisome; ISO:RGD.
DR   GO; GO:0044754; C:autolysosome; ISO:RGD.
DR   GO; GO:0005776; C:autophagosome; ISS:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; ISO:RGD.
DR   GO; GO:0005829; C:cytosol; ISO:RGD.
DR   GO; GO:0005783; C:endoplasmic reticulum; IEA:UniProtKB-SubCell.
DR   GO; GO:0098978; C:glutamatergic synapse; IDA:SynGO.
DR   GO; GO:0016234; C:inclusion body; ISO:RGD.
DR   GO; GO:0043232; C:intracellular non-membrane-bounded organelle; ISS:UniProtKB.
DR   GO; GO:0005770; C:late endosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0097413; C:Lewy body; IDA:RGD.
DR   GO; GO:0005739; C:mitochondrion; ISO:RGD.
DR   GO; GO:0000932; C:P-body; ISS:UniProtKB.
DR   GO; GO:0000407; C:phagophore assembly site; ISO:RGD.
DR   GO; GO:0016605; C:PML body; ISO:RGD.
DR   GO; GO:0030017; C:sarcomere; IEA:UniProtKB-SubCell.
DR   GO; GO:0097225; C:sperm midpiece; ISO:RGD.
DR   GO; GO:0045202; C:synapse; IDA:SynGO.
DR   GO; GO:0019899; F:enzyme binding; ISO:RGD.
DR   GO; GO:0042802; F:identical protein binding; IPI:RGD.
DR   GO; GO:0035255; F:ionotropic glutamate receptor binding; ISO:RGD.
DR   GO; GO:0070530; F:K63-linked polyubiquitin modification-dependent protein binding; ISS:UniProtKB.
DR   GO; GO:0140693; F:molecular condensate scaffold activity; ISO:RGD.
DR   GO; GO:0140313; F:molecular sequestering activity; ISO:RGD.
DR   GO; GO:0019901; F:protein kinase binding; ISO:RGD.
DR   GO; GO:0005080; F:protein kinase C binding; IPI:RGD.
DR   GO; GO:0140311; F:protein sequestering activity; ISS:UniProtKB.
DR   GO; GO:0044877; F:protein-containing complex binding; IPI:RGD.
DR   GO; GO:0030674; F:protein-macromolecule adaptor activity; ISS:UniProtKB.
DR   GO; GO:0042169; F:SH2 domain binding; ISS:UniProtKB.
DR   GO; GO:0035591; F:signaling adaptor activity; ISO:RGD.
DR   GO; GO:0038023; F:signaling receptor activity; ISO:RGD.
DR   GO; GO:0043130; F:ubiquitin binding; ISS:UniProtKB.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; ISO:RGD.
DR   GO; GO:0140036; F:ubiquitin-modified protein reader activity; ISS:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0035973; P:aggrephagy; ISS:UniProtKB.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0006914; P:autophagy; ISS:UniProtKB.
DR   GO; GO:0070342; P:brown fat cell proliferation; ISO:RGD.
DR   GO; GO:0030154; P:cell differentiation; IEA:UniProtKB-KW.
DR   GO; GO:0007032; P:endosome organization; ISS:UniProtKB.
DR   GO; GO:0097009; P:energy homeostasis; ISO:RGD.
DR   GO; GO:0002376; P:immune system process; IEA:UniProtKB-KW.
DR   GO; GO:0016236; P:macroautophagy; ISS:UniProtKB.
DR   GO; GO:0000423; P:mitophagy; ISO:RGD.
DR   GO; GO:0110076; P:negative regulation of ferroptosis; ISS:UniProtKB.
DR   GO; GO:0031397; P:negative regulation of protein ubiquitination; ISS:UniProtKB.
DR   GO; GO:0034144; P:negative regulation of toll-like receptor 4 signaling pathway; ISO:RGD.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; ISO:RGD.
DR   GO; GO:0140694; P:non-membrane-bounded organelle assembly; ISO:RGD.
DR   GO; GO:0000425; P:pexophagy; ISS:UniProtKB.
DR   GO; GO:0010508; P:positive regulation of autophagy; ISO:RGD.
DR   GO; GO:1900273; P:positive regulation of long-term synaptic potentiation; ISO:RGD.
DR   GO; GO:1903078; P:positive regulation of protein localization to plasma membrane; ISO:RGD.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IDA:RGD.
DR   GO; GO:0030163; P:protein catabolic process; ISS:UniProtKB.
DR   GO; GO:0006606; P:protein import into nucleus; ISO:RGD.
DR   GO; GO:1905719; P:protein localization to perinuclear region of cytoplasm; ISS:UniProtKB.
DR   GO; GO:0071211; P:protein targeting to vacuole involved in autophagy; ISS:UniProtKB.
DR   GO; GO:0043122; P:regulation of canonical NF-kappaB signal transduction; ISS:UniProtKB.
DR   GO; GO:0061635; P:regulation of protein complex stability; ISO:RGD.
DR   GO; GO:0002931; P:response to ischemia; IEP:RGD.
DR   GO; GO:0098780; P:response to mitochondrial depolarisation; ISO:RGD.
DR   GO; GO:0001659; P:temperature homeostasis; ISO:RGD.
DR   GO; GO:0006366; P:transcription by RNA polymerase II; ISO:RGD.
DR   CDD; cd06402; PB1_p62; 1.
DR   CDD; cd14320; UBA_SQSTM; 1.
DR   CDD; cd02340; ZZ_NBR1_like; 1.
DR   Gene3D; 3.30.60.90; -; 1.
DR   Gene3D; 1.10.8.10; DNA helicase RuvA subunit, C-terminal domain; 1.
DR   IDEAL; IID50133; -.
DR   InterPro; IPR052260; Autophagy_Rcpt_SigReg.
DR   InterPro; IPR053793; PB1-like.
DR   InterPro; IPR000270; PB1_dom.
DR   InterPro; IPR034866; PB1_p62.
DR   InterPro; IPR033741; SQSTM_UBA.
DR   InterPro; IPR015940; UBA.
DR   InterPro; IPR009060; UBA-like_sf.
DR   InterPro; IPR000433; Znf_ZZ.
DR   InterPro; IPR043145; Znf_ZZ_sf.
DR   PANTHER; PTHR15090; SEQUESTOSOME 1-RELATED; 1.
DR   PANTHER; PTHR15090:SF0; SEQUESTOSOME-1; 1.
DR   Pfam; PF00564; PB1; 1.
DR   Pfam; PF16577; UBA_5; 1.
DR   Pfam; PF00569; ZZ; 1.
DR   SMART; SM00666; PB1; 1.
DR   SMART; SM00165; UBA; 1.
DR   SMART; SM00291; ZnF_ZZ; 1.
DR   SUPFAM; SSF54277; CAD & PB1 domains; 1.
DR   SUPFAM; SSF57850; RING/U-box; 1.
DR   SUPFAM; SSF46934; UBA-like; 1.
DR   PROSITE; PS51745; PB1; 1.
DR   PROSITE; PS50030; UBA; 1.
DR   PROSITE; PS01357; ZF_ZZ_1; 1.
DR   PROSITE; PS50135; ZF_ZZ_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Apoptosis; Autophagy;
KW   Cytoplasm; Cytoplasmic vesicle; Differentiation; Endoplasmic reticulum;
KW   Endosome; Immunity; Isopeptide bond; Lipoprotein; Lysosome; Metal-binding;
KW   Nucleus; Palmitate; Phosphoprotein; Reference proteome; Ubl conjugation;
KW   Zinc; Zinc-finger.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000250|UniProtKB:Q13501"
FT   CHAIN           2..439
FT                   /note="Sequestosome-1"
FT                   /id="PRO_0000072179"
FT   DOMAIN          3..100
FT                   /note="PB1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01081"
FT   DOMAIN          388..433
FT                   /note="UBA"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00212"
FT   ZN_FING         120..170
FT                   /note="ZZ-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00228"
FT   REGION          2..48
FT                   /note="Interaction with LCK"
FT                   /evidence="ECO:0000250|UniProtKB:Q13501"
FT   REGION          41..105
FT                   /note="Interaction with PRKCZ and dimerization"
FT                   /evidence="ECO:0000269|PubMed:10477520,
FT                   ECO:0000269|PubMed:12431995"
FT   REGION          48..78
FT                   /note="Interaction with PAWR"
FT                   /evidence="ECO:0000250|UniProtKB:Q13501"
FT   REGION          119..221
FT                   /note="Interaction with GABRR3"
FT                   /evidence="ECO:0000269|PubMed:12431995"
FT   REGION          167..217
FT                   /note="LIM protein-binding"
FT                   /evidence="ECO:0000250|UniProtKB:Q13501"
FT   REGION          201..231
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          259..389
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          266..439
FT                   /note="Interaction with NTRK1"
FT                   /evidence="ECO:0000269|PubMed:11244088"
FT   REGION          320..341
FT                   /note="MAP1LC3B-binding"
FT                   /evidence="ECO:0000250|UniProtKB:Q13501"
FT   REGION          346..351
FT                   /note="Interaction with KEAP1"
FT                   /evidence="ECO:0000250|UniProtKB:Q64337"
FT   MOTIF           225..230
FT                   /note="TRAF6-binding"
FT                   /evidence="ECO:0000250"
FT   MOTIF           335..340
FT                   /note="LIR"
FT   COMPBIAS        265..293
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        343..371
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   BINDING         125
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00228"
FT   BINDING         128
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00228"
FT   BINDING         139
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00228"
FT   BINDING         142
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00228"
FT   BINDING         148
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00228"
FT   BINDING         151
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00228"
FT   BINDING         157
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00228"
FT   BINDING         160
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00228"
FT   MOD_RES         2
FT                   /note="N-acetylalanine"
FT                   /evidence="ECO:0000250|UniProtKB:Q13501"
FT   MOD_RES         24
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q13501"
FT   MOD_RES         145
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:Q13501"
FT   MOD_RES         173
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q13501"
FT   MOD_RES         175
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q64337"
FT   MOD_RES         204
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q13501"
FT   MOD_RES         246
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q13501"
FT   MOD_RES         263
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q13501"
FT   MOD_RES         266
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         269
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q13501"
FT   MOD_RES         281
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q13501"
FT   MOD_RES         305
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q13501"
FT   MOD_RES         327
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q13501"
FT   MOD_RES         331
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q13501"
FT   MOD_RES         348
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q64337"
FT   MOD_RES         354
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         360
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q13501"
FT   MOD_RES         364
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q64337"
FT   MOD_RES         365
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q13501"
FT   MOD_RES         402
FT                   /note="Phosphoserine; by ULK1 and TBK1"
FT                   /evidence="ECO:0000250|UniProtKB:Q13501"
FT   MOD_RES         406
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q13501"
FT   MOD_RES         419
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q13501"
FT   MOD_RES         434
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q13501"
FT   LIPID           288
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000250|UniProtKB:Q13501"
FT   CROSSLNK        419
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin); alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q13501"
FT   CROSSLNK        434
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q13501"
FT   VAR_SEQ         222..248
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_015843"
FT   VAR_SEQ         222..234
FT                   /note="ASAPSEDPNVNFL -> GKAGVCTGFKCHK (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:12431995"
FT                   /id="VSP_015844"
FT   VAR_SEQ         235..439
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:12431995"
FT                   /id="VSP_015845"
FT   MUTAGEN         7
FT                   /note="K->A: Loss of interaction with PRKCI."
FT                   /evidence="ECO:0000269|PubMed:15143057"
FT   MUTAGEN         21..22
FT                   /note="RR->AA: Reduces interaction with PRKCI."
FT                   /evidence="ECO:0000269|PubMed:15143057"
FT   MUTAGEN         67
FT                   /note="D->A: No effect on interaction with PRKCI. Abolishes
FT                   homooligomerization; when associated with A-67."
FT                   /evidence="ECO:0000269|PubMed:15143057,
FT                   ECO:0000269|PubMed:19728111"
FT   MUTAGEN         69
FT                   /note="D->A: Abolishes homooligomerization; when associated
FT                   with A-67."
FT                   /evidence="ECO:0000269|PubMed:19728111"
FT   MUTAGEN         94
FT                   /note="R->A: Reduces interaction with PRKCI."
FT                   /evidence="ECO:0000269|PubMed:15143057"
FT   STRAND          3..11
FT                   /evidence="ECO:0007829|PDB:2KKC"
FT   STRAND          13..15
FT                   /evidence="ECO:0007829|PDB:2KKC"
FT   STRAND          17..29
FT                   /evidence="ECO:0007829|PDB:2KKC"
FT   STRAND          33..35
FT                   /evidence="ECO:0007829|PDB:2KKC"
FT   HELIX           41..52
FT                   /evidence="ECO:0007829|PDB:2KKC"
FT   STRAND          61..66
FT                   /evidence="ECO:0007829|PDB:2KKC"
FT   STRAND          72..75
FT                   /evidence="ECO:0007829|PDB:2KKC"
FT   HELIX           78..87
FT                   /evidence="ECO:0007829|PDB:2KKC"
FT   STRAND          90..99
FT                   /evidence="ECO:0007829|PDB:2KKC"
SQ   SEQUENCE   439 AA;  47681 MW;  E611F296E2B11464 CRC64;
     MASLTVKAYL LGKEEAAREI RRFSFCFSPE PEAEAAAGPG PCERLLSRVA VLFPALRPGG
     FQAHYRDEDG DLVAFSSDEE LTMAMSYVKD DIFRIYIKEK KECRREHRPP CAQEARSMVH
     PNVICDGCNG PVVGTRYKCS VCPDYDLCSV CEGKGLHREH SKLIFPNPFG HLSDSFSHSR
     WLRKLKHGHF GWPGWEMGPP GNWSPRPPRA GDGRPCPTAE SASAPSEDPN VNFLKNVGES
     VAAALSPLGI EVDIDVEHGG KRSRLTPTSA ESSSTGTEDK SGTQPSSCSS EVSKPDGAGE
     GPAQSLTEQM KKIALESVGQ PEELMESDNC SGGDDDWTHL SSKEVDPSTG ELQSLQMPES
     EGPSSLDPSQ EGPTGLKEAA LYPHLPPEAD PRLIESLSQM LSMGFSDEGG WLTRLLQTKN
     YDIGAALDTI QYSKHPPPL
//
